Browse the evidence

Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates superior glycemic control and weight loss compared to semaglutide and insulin degludec in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and struggle with blood sugar control and weight loss despite other medications, ask your doctor about tirzepatide (Mounjaro). This weekly injection targets two hormones (GIP and GLP-1) and has been shown to be more effective than semaglutide and insulin degludec in lowering blood sugar and reducing weight.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg and liraglutide 3.0 mg) are the most effective pharmacotherapeutic interventions for weight loss in adults with obesity, significantly outperforming placebo and other agents.

For adults with obesity, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are the most effective medication options for weight loss, producing significantly greater weight reduction than placebo or other drugs. While gastrointestinal side effects like nausea are common, the overall safety profile is favorable, making these a promising treatment option when lifestyle changes alone are insufficient.

Semaglutide (2.4 mg weekly) produces significantly greater weight loss (15.8%) compared to liraglutide (6.4%) in patients without type 2 diabetes.

If you are struggling with weight loss despite diet and exercise, semaglutide (Wegovy) is currently the most effective registered medication, offering about 15.8% average weight loss over 68 weeks when combined with lifestyle changes. It is taken as a once-weekly injection, which is less frequent than daily options like liraglutide.

Weekly subcutaneous semaglutide (2.4 mg) produces significantly greater mean weight loss (15.4%) compared to daily subcutaneous liraglutide (3.0 mg, 6.4%) in patients with overweight or obesity.

If you are struggling with obesity, talk to your doctor about Semaglutide. It is a once-weekly injection that has been shown to help people lose significantly more weight than older medications like Liraglutide. Start with a low dose to minimize side effects and work your way up to the full dose over several months.

Tirzepatide (TZP) reduces the risk of four-component major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes (T2DM) and obesity compared to placebo, with the 15mg dose showing the most significant reduction.

If you have T2DM or obesity, Tirzepatide (TZP) can significantly lower your risk of major cardiovascular events (like heart attack or stroke) compared to a placebo. The 15mg dose is the most effective for heart protection, but it also comes with a higher risk of side effects like nausea. Patients with T2DM seem to get more heart benefits and fewer side effects than those with obesity alone. Talk to your doctor about whether the cardiovascular benefits outweigh the potential side effects for you.

Antiobesity medications (AOMs), particularly GLP-1/GIP receptor agonists like semaglutide and tirzepatide, are effective adjuncts to lifestyle modifications for achieving clinically significant weight loss (>5-10% total body weight) in patients with BMI >30 (or >27 with comorbidities).

If you have a BMI over 30 (or 27 with health issues), lifestyle changes alone may not be enough for lasting results. Talk to your doctor about GLP-1/GIP medications like semaglutide or tirzepatide. These are weekly injections that help with appetite and satiety. They work best when combined with diet and exercise changes, and your doctor should monitor your nutrition to prevent deficiencies.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces clinically meaningful weight loss (average 15-25% over 88 weeks) superior to placebo and semaglutide in adults with obesity or overweight.

If you have obesity or overweight with related health issues, Tirzepatide is an FDA-approved, once-weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. Clinical trials show it leads to significant weight loss (up to 25% over nearly 2 years), often more than other popular drugs like semaglutide. It requires a calorie-restricted diet and exercise. Common side effects are gastrointestinal (nausea/diarrhea), but serious risks are rare. It is contraindicated for those with a history of medullary thyroid cancer.

New incretin-based anti-obesity drugs (GLP-1, GIP, and triple agonists) achieve weight loss magnitudes (up to 25%) comparable to bariatric surgery by enhancing satiety and inhibiting hunger through central nervous system mechanisms.

If lifestyle changes alone aren't enough, newer incretin-based medications (like semaglutide or tirzepatide) are highly effective, offering weight loss up to 25% by targeting hunger and satiety signals in the brain. They are taken as weekly injections and are intended for long-term use, similar to how other chronic conditions are managed. While costly, they offer a non-surgical alternative with efficacy approaching bariatric surgery.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior glycemic control and weight loss compared to other current pharmacotherapies for type 2 diabetes.

Tirzepatide is a once-weekly injection that helps lower blood sugar and lose weight more effectively than many current diabetes drugs. It works by mimicking hormones that regulate insulin and appetite. While nausea is a common side effect, most people tolerate it well, and only a small percentage stop taking it. It is particularly useful for those who struggle with weight gain from other diabetes medications.

Multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 receptor agonists (orforglipron) are emerging treatments that reduce body weight and improve metabolic health.

Newer multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 agonists (orforglipron) are in clinical trials or recently approved, offering once-weekly or daily options to reduce body weight and improve cardiac metabolism in adults with obesity.

Phenotype-guided pharmacotherapy (matching drug mechanism to obesity phenotype) yields significantly greater weight loss than non-phenotype-guided approaches.

If you are struggling with obesity, ask your doctor about 'phenotyping.' Instead of just taking the most common weight loss drug, see if your specific type of hunger (e.g., emotional, hormonal, or slow metabolism) matches a specific medication. This personalized matching has been shown to result in significantly more weight loss than standard approaches.

Tirzepatide (5-15 mg once weekly) produces superior weight loss (16.5% to 22.4%) and glycemic control compared to GLP-1 monotherapies (liraglutide, semaglutide) and other glucose-lowering medications in patients with type 2 diabetes and obesity.

For adults with obesity or type 2 diabetes, tirzepatide (5-15 mg weekly) is a highly effective treatment that significantly reduces body weight (up to ~21%) and improves cardiovascular risk factors more than GLP-1 monotherapies like semaglutide or liraglutide. It requires weekly injections and lifestyle changes, with side effects like nausea being common but usually mild and temporary during dose increases.

Liraglutide (3.0 mg once daily) combined with lifestyle changes is an effective treatment for obesity in patients with and without type 2 diabetes, resulting in significant weight loss and maintenance.

Liraglutide 3.0 mg taken once daily, combined with lifestyle changes, is an effective treatment for obesity in adults with or without type 2 diabetes. It leads to significant weight loss (average ~7.8% in some trials) and helps maintain weight loss, with benefits extending to clinical comorbidities.

Semaglutide (≥0.2 mg once weekly) demonstrates statistically significant weight loss compared to liraglutide 3.0 mg in patients with obesity without diabetes.

For obese adults without diabetes, semaglutide doses of 0.2 mg or higher (weekly) result in greater weight loss than liraglutide 3.0 mg (daily).

Incretin-based therapies (GLP-1 and GLP-1/GIP dual agonists) provide superior glycemic control and weight loss compared to basal insulin in Type 2 Diabetes, with lower hypoglycemia risk.

If you have Type 2 Diabetes and need an injection, ask about GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) before starting insulin. These drugs lower blood sugar better, help you lose weight, and carry a lower risk of dangerous low blood sugar events, though you may experience temporary stomach upset.

Anti-obesity medications (AOMs) combined with lifestyle modifications produce greater and more sustained weight loss (5-23%) compared to lifestyle changes alone, with specific agents like semaglutide and tirzepatide showing superior efficacy.

If you have obesity, lifestyle changes alone are often insufficient for long-term success due to biological factors. FDA-approved medications like semaglutide or tirzepatide, when combined with lifestyle changes, can produce significant weight loss (16-23%). These medications are intended for long-term use. Discuss with your doctor if you are a candidate, considering potential side effects and costs.

Preoperative and postoperative pharmacotherapy with GLP-1 agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) significantly enhances weight loss outcomes and reduces weight regain after bariatric surgery.

Using GLP-1 or dual agonists like semaglutide or tirzepatide before or after bariatric surgery can significantly boost weight loss results and prevent the common problem of weight regain, offering a powerful tool for long-term metabolic health.

GLP-1 receptor agonists (semaglutide 2.4 mg/week, tirzepatide 15 mg/week) produce significant weight loss (10–21%) and metabolic improvements in adults with obesity, though outcomes are limited by gastrointestinal side effects and long-term adherence challenges.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (10-21%) and improving metabolic health. They work by slowing digestion and reducing appetite. Expect gastrointestinal side effects like nausea, which often improve over time. These drugs require ongoing use and can be expensive, so discuss insurance coverage and side effect management with your doctor.

Incretin-based therapies (GLP-1 and dual GIP/GLP-1 receptor agonists) administered for 12 months in adults with obesity and type 2 diabetes significantly reduce body weight, improve glycemic control, and provide multi-organ protection (cardiovascular, renal, and hepatic).

If you have obesity and type 2 diabetes, incretin-based medications (like semaglutide or tirzepatide) are highly effective for losing weight (average 10.7%), lowering blood sugar, and protecting your heart, kidneys, and liver. These benefits are consistent across different healthcare settings in Latin America. Discuss these options with your doctor, especially if you are concerned about injection frequency, as oral alternatives are emerging.

Dual and triple incretin agonists (e.g., tirzepatide, retatrutide) offer superior weight loss and glycemic control compared to single GLP-1 agonists.

Newer medications that target multiple hormones (like tirzepatide and retatrutide) are showing even greater weight loss and blood sugar control than older GLP-1 drugs. While promising, they require careful monitoring for long-term safety. These options may be considered if single-agonist therapies are insufficient.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to semaglutide and other GLP-1 receptor agonists in patients with type 2 diabetes.

If you have Type 2 Diabetes and struggle with weight loss, Tirzepatide (brand name Tirzetta in Russia) is currently the most effective incretin-based treatment available. It works by mimicking two gut hormones (GIP and GLP-1) to improve blood sugar control and promote significant weight loss. Treatment starts with a low dose (2.5 mg weekly) to minimize side effects, then increases every 4 weeks up to 15 mg as needed. It is administered via a user-friendly auto-injector once a week alongside a calorie-controlled diet and exercise.

Combination therapies involving GLP-1 receptor agonists (GLP-1RAs) and insulin, or comprehensive metabolic interventions including metformin, significantly increase diabetes remission rates compared to standard care.

Ask your doctor about a short-term (12-week) intensive program combining lifestyle changes, insulin, GLP-1 medication, and metformin. This aggressive approach can double your chances of reversing diabetes and potentially stop all medications long-term.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant potential for achieving prediabetes and type 2 diabetes remission through superior glycemic control and weight loss compared to other GLP-1RAs.

Ask your doctor about tirzepatide, a dual-acting medication that targets both GIP and GLP-1 receptors. It has shown exceptional results in achieving remission and significant weight loss, potentially offering a path to stopping other diabetes medications.

Tirzepatide, a dual GIP/GLP-1 agonist, achieves greater weight loss (up to 22.5%) than GLP-1RAs alone, making it the most effective pharmacological weight loss therapy currently available.

If standard GLP-1 drugs aren't enough, ask your doctor about tirzepatide. It targets two hormones (GLP-1 and GIP) to help you lose more weight (up to 22.5%) than GLP-1 drugs alone. It is taken once weekly. Like other drugs in this class, it may cause digestive issues, but it is currently the most effective non-surgical medication for weight loss.